A corrigendum on Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study by Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, et al. Front Immunol (2017) 8:386. doi: 10.3389/fimmu.2017.00386. In the original article, affiliation number 9 was wrong. The correct affiliation 9 is "Istituto Dermopatico dell'Immacolata IDI-IRCCS, Rome, Italy". This error does not change the scientific conclusions of the article in any way. The original article has been updated. Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Corrigendum: Association of CTLA-4 gene variants with response to therapy and long-term survival in metastatic melanoma patients treated with ipilimumab: An Italian melanoma intergroup study [Front Immunol, 8, (2017), (386)] doi: 10.3389/fimmu.2017.00386

Morabito A.;Fava C.;Capone M.;Pagani E.;Marchetti P.;Quaglino P.;Fava P.;Spagnolo F.;
2018-01-01

Abstract

A corrigendum on Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study by Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, et al. Front Immunol (2017) 8:386. doi: 10.3389/fimmu.2017.00386. In the original article, affiliation number 9 was wrong. The correct affiliation 9 is "Istituto Dermopatico dell'Immacolata IDI-IRCCS, Rome, Italy". This error does not change the scientific conclusions of the article in any way. The original article has been updated. Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
2018
Inglese
Esperti anonimi
8
MAR
386
394
9
Best overall response; CTLA-4 variants; Ipilimumab; Melanoma; Overall survival; Predictive/prognostic factor
no
2 – prodotto con deroga d’ufficio (SOLO se editore non consente/non ha risposto)
262
31
Queirolo P.; Dozin B.; Morabito A.; Banelli B.; Piccioli P.; Fava C.; Leo C.; Carosio R.; Laurent S.; Fontana V.; Ferrucci P.F.; Martinoli C.; Cocoroc...espandi
info:eu-repo/semantics/article
none
03-CONTRIBUTO IN RIVISTA::03A-Articolo su Rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1890637
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 3
social impact